Published: 19 March 2025
Author(s): Ruggiero Mascolo, Maddalena Alessandra Wu, Silvia Berra, Matteo Vidali, Massimo Pancrazi, Lucia Trotta, Elisa Ceriani, Enrica Negro, Lisa Serati, Luisa Carrozzo, Elisa Calabrò, Ferruccio Ceriotti, Alessandro Andreis, Valentino Collini, Massimo Imazio, Antonio Brucato
Section: Original Article
Idiopathic recurrent acute pericarditis (IRAP) significantly affects patients’ quality of life, imposing a psychosocial burden, alongside risks of complications, treatment-related adverse effects, and healthcare resource strain [1–3].
